8-K: Allurion Technologies Announces 1-for-15 Reverse Stock Split

Allurion Technologies, Inc. has implemented a 1-for-15 reverse stock split to regain compliance with NYSE listing standards and advance its relisting strategy.

Summary

• Allurion Technologies, Inc. has executed a 1-for-15 reverse stock split of its common stock, effective June 18, 2026.
• This action is intended to support the company's efforts to regain compliance with the continued listing requirements of the New York Stock Exchange (NYSE) or meet the initial listing requirements of the NYSE American.
• The reverse stock split will reduce the number of outstanding shares from approximately 15,006,253 to approximately 1,000,417.
• Trading on the OTCQB Market will commence on a split-adjusted basis under the temporary symbol 'ALURD' for twenty days, after which it will revert to 'ALUR'.
• Fractional shares will be rounded up to the next whole share.
• Adjustments will be made to equity incentive plans, stock options, restricted stock units, convertible notes, and warrants to reflect the split.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it's a necessary step to address listing compliance issues and improve market positioning, but it does not inherently change the company's fundamental business performance.

Positives

• The reverse stock split is a strategic move to improve the company's capital markets positioning and enhance shareholder liquidity.
• Regaining NYSE listing compliance is expected to increase visibility and support long-term growth.
• The company is actively engaging with national exchanges to advance its relisting strategy.
• Fractional shares will be rounded up, benefiting stockholders who would otherwise receive a fraction.

Negatives

• The company is currently not in compliance with NYSE continued listing standards, necessitating this reverse stock split.
• The temporary trading symbol 'ALURD' may cause short-term confusion for investors.
• The exercise price for warrants has significantly increased ($3,037.50 per share) due to the split.

Risks

• The risk of noncompliance with NYSE continued listing standards may impact the company's results of operations, business operations, and reputation.
• There is a risk that the company may not be able to regain compliance with NYSE continued listing standards or satisfy the initial listing standards of another nationally recognized securities exchange.
• The company's ability to complete a transaction to achieve compliance with listing standards is uncertain.
• Global economic conditions and geopolitical events could impact the company's business.
• The company faces risks related to maintaining regulatory approvals and commercializing its products, including the Allurion Balloon.
• The timing and results of clinical studies and trials are subject to uncertainty.
• The company must defend its intellectual property and satisfy regulatory requirements.

Future Outlook

The company aims to regain compliance with NYSE listing standards or meet the initial listing requirements of the NYSE American through the reverse stock split and ongoing engagement with national exchanges. The company believes relisting will enhance visibility, improve liquidity, and better position Allurion for long-term growth.

Management Comments

• We believe re-listing will enhance our visibility, improve liquidity for our shareholders, and better position Allurion for long-term growth as we continue to execute on our U.S. commercial strategy.
• We have had a constructive and collaborative dialogue with the national exchanges throughout this process, and we remain focused on meeting all requirements necessary to regain our listing.

Industry Context

StockSavvy.ai notes that reverse stock splits are often employed by companies seeking to meet exchange listing requirements, particularly when facing delisting due to low share prices. This is a common strategy in the highly competitive and often volatile biotechnology and medical device sectors.

Corporate Governance

Stakeholder Impact

• Shareholders will see their number of shares reduced by a factor of 15, with fractional shares rounded up.
• Holders of stock options, RSUs, and convertible notes will experience proportional adjustments to their holdings and exercise/conversion terms.
• Warrant holders will have their exercise price adjusted significantly upwards and the number of shares per warrant adjusted.

Next Steps

• Trading on the OTCQB Market under the temporary symbol ALURD for twenty days.
• Reversion of trading symbol to ALUR after twenty business days.
• Continued engagement with national exchanges to meet listing requirements.
• Execution of the U.S. commercial strategy.

Key Dates

Recommendation

The reverse stock split is a procedural step to address listing requirements rather than a fundamental business change. While it aims to improve market positioning, the company's ability to regain listing and achieve long-term growth remains subject to its core business performance and market conditions. Therefore, a 'hold' recommendation is appropriate pending further developments.

Keywords

reverse stock split, Allurion Technologies, NYSE listing, OTCQB, stock adjustment, capital markets, weight loss, corporate governance